Delivery Order SPE2DB24D2106-SPE2DB26FAUAE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4.7 million to DMS Pharmaceutical Group Inc. for 90-count tablets of Jardiance 25 mg, a diabetes medication. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 9, 2025. The contract utilizes a firm fixed-price structure with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $31,518.19 to DMS Pharmaceutical Group Inc. for 90 tablets of Jardiance 25 mg, a diabetes medication. The award was issued on August 18, 2025, with an ultimate completion date of August 19, 2025. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, a $499.9 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $3,686.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jardiance 25 mg tablets (90-count units). The delivery order, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, represents a firm fixed-price contract with no set-aside designation. Performance will be executed at the company's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $10,772.99 to DMS Pharmaceutical Group Inc. for the supply of Jardiance 25 mg tablets (90-count units). This firm fixed-price delivery order, issued on September 15, 2025, represents fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $499,999,999 through November 2026. The contract carries no set-aside designation. Performance will be completed by September 16, 2025, with the...
- The U.S. Department of Defense's Defense Logistics Agency Troop Support Medical awarded a firm-fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide Jardiance 25 mg tablets. The order has a potential value of $4,094.64 and is set to be completed by February 9, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that holds an indefinite delivery contract with the Defense Logistics Agency, valued at...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $7,162.08 to DMS Pharmaceutical Group Inc. for the supply of Jardiance 25 mg tablets (90-count packages). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform delivery to Conshohocken, Pennsylvania by the August 22, 2025 completion date. This delivery order was awarded without set-aside designation and represents a continuation of DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was awarded a firm fixed-price delivery order valued at $8,512.19 by the Defense Logistics Agency (DLA) on September 19, 2025, for the supply of Jardiance 25 mg tablets in quantities of 90. The delivery order, which carries no set-aside designation, is scheduled for completion by September 22, 2025, with performance to take place in Conshohocken, Pennsylvania. This award represents a discrete delivery order...
- The Defense Logistics Agency awarded a $17.8K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jardiance 25 mg tablets (90-count units). The delivery order, issued on April 21, 2025, with an ultimate completion date of April 22, 2025, carries no set-aside designation. This award represents a continuation of DMS Pharmaceutical Group's established role as a critical supplier...
- The Defense Logistics Agency awarded a delivery order valued at $30,010.06 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jardiance 10 mg tablets in quantities of 90. The contract employs a firm fixed-price structure with an ultimate completion date of September 12, 2025, and carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract...
- This delivery order, valued at $5,089.90, awards DMS Pharmaceutical Group Inc. a firm fixed-price contract for Jardiance 10 mg tablets (90-count supply) to support Department of Defense medical supply requirements. The order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at $499,999,999 and valid through November 2026. Performance will be executed from the vendor's location in...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB26FAUAEDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,631.11 to DMS Pharmaceutical Group Inc. for 90-count tablets of Jardiance 25 mg, an oral diabetes medication. This firm fixed-price delivery order was issued on October 29, 2025, with an ultimate completion date of October 30, 2025, and represents a routine pharmaceutical supply transaction issued without set-aside designation. The place of performance is Conshohocken, Pennsylvania. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, serves as a critical supplier within the federal military medical supply chain. This delivery order was issued under the company's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a broader $30.3 billion acquisition strategy that authorizes DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables supporting Department of Defense healthcare operations globally. The PPV-G GEN V contract awarded to DMS Pharmaceutical Group carries a $499.999 billion ceiling value through December 31, 2036, positioning the company as a regional prime vendor contractor within this multi-award framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 10/29/25 |